Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2007-09-25
2007-09-25
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S009100, C424S130100, C424S184100, C424S234100, C424S248100, C424S278100, C435S253100
Reexamination Certificate
active
10484079
ABSTRACT:
An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided.A pharmaceutical composition which comprises a bacterial component as an effective ingredient is disclosed, which is used for immunotherapy in a patient suffering from a cancer or microbial infection, wherein the immunotherapy comprises eradicating the cancer cells or the microorganisms from the lymph nodes of the patient.
REFERENCES:
patent: 4503048 (1985-03-01), Cantrell
patent: 4726947 (1988-02-01), Shimada et al.
patent: 4744984 (1988-05-01), Ragland
patent: 4746511 (1988-05-01), Kobatake et al.
patent: 6001361 (1999-12-01), Tan et al.
patent: 6593096 (2003-07-01), Hayashi et al.
patent: 2003/0108527 (2003-06-01), Seya et al.
patent: 958826 (1999-11-01), None
patent: 1 097 715 (2001-05-01), None
patent: WO-98/43655 (1998-10-01), None
patent: WO-99/55347 (1999-11-01), None
patent: WO 00/03724 (2000-01-01), None
C.A. Janeway, Jr., Cold Spring Harbor Symp. Quant. Biol., 54, 1-13 (1989).
R. Medzhitov et al., Cell, 91, 295-298 (Oct. 31, 1997).
Proceedings Amer. Assoc. Cancer Res., 89thAnnual Meeting, vol. 39, p. 529, Abstract #3598, A. Hayashi, et al., Independent Use of BCG-CWS Effectively Attacks Lymphnode Metastasis of Cancer (Mar. 28-Apr. 1, 1998).
Proceedings Amer. Assoc. Cancer Res., 90thAnnual Meeting, vol. 40, p. 657, Abstract #4333, A. Hayashi, Requirement for costimulatory molecules in effective cancer immunotherapy with BCG-Cell wall skeleton (Apr. 10-14, 1999).
Hayashi et al, Proceedings of the Japan Academy, Series B: Physical and Biological Sciences, 1998, vol. 74, No. 3, pp. 50-55.
Hayashi et al. Proceedings of the Japan Academy, Series B: Physical and Biological Sciences, 1994, vol. 70, No. 10, pp. 205-209.
Hayashi et al, “Complete cure of acute myelocyte leukemia with BCG-cell wall skeleton alone”, Journal of Haematology, vol. 102, p. 85.
Database WPI Section Ch, Week 198428 Derment Publications Ltd., London, GB; AN 1984-173727 XP002350966 & JP 59 095220 A (Ajinomoto KK) Jun. 1, 1984.
Seya et al: “Innate immune therapy for cancer. Screen for molecules capable of activating the innate immune system.” Advances in Experimental Medicine and Biology, 465 p. 229-237. Ref: 30 Journal Code: 0121103. ISSN: 0065-2598. 2000, XP008054070.
Toyoshima, “Reevaluation of Immunopotentiation Therapy for Canser”, Japanese Journal of Cancer and Chemotherapy, 2000, vol. 27, No. 6, pp. 817-823.
H. Akira, “A New Trend of Cancer Immunotherapy: BCG-CWS as a Bridge Between the Innate Immunity and the Acquired”, Mol Med, 36, 220-229 (1999) (English Abstract).
Akira Hayashi, “Kenko Shihyo Project Series 40 Gan Vaccine No Sayo Kisaku To Men'eki Ryoho 2 BCG-CWS O Mochiiru Gan Tandoku Men'eke Ryoho 30 Nen No Kiroku”, Environment and Health, Oct. 2001, vol. 14, No. 5, pp. 259-270.
Azuma Ichiro
Birch & Stewart Kolasch & Birch, LLP
Hayashi Akira
Swartz Rodney P.
Toyoshima Kumao
LandOfFree
Immunotherapy for humans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy for humans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy for humans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736793